NCT00085917View on ClinicalTrials.gov

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Hepatitis CHIV Infections
Interventions
DRUG

Double dose pegylated interferon with weight based Ribavirin

pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment

DRUG

standard dose pegylated interferon alfa -2a and ribavirin

pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00085917 - Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients | Biotech Hunter | Biotech Hunter